Literature DB >> 9572548

Transient marker stabilisation: a general procedure to construct marker-free recombinant vaccinia virus.

F Scheiflinger1, F Dorner, F G Falkner.   

Abstract

Recombinant vaccinia viruses based on the highly attenuated Modified Vaccinia Ankara (MVA) strain expressing HIV-1 antigen genes were constructed by a novel procedure involving the transient use of two marker genes. The selectable markers used, the Escherichia coli guanine phosphoribosyltransferase (gpt) and the beta-galactosidase (lacZ) genes, are not retained within the final recombinant virus. The transient marker stabilisation (TMS) procedure allows the generation of marker-free recombinant viruses in a series of simple plaque purification steps. HIV-1 gag pol genes were inserted into two loci of vaccinia MVA demonstrating the efficiency of the procedure.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9572548     DOI： 10.1007/s007050050303

Source DB:  PubMed          Journal:  Arch Virol        ISSN： 0304-8608            Impact factor:   2.574


  12 in total

1.  Recombinant vaccinia viruses. Design, generation, and isolation.

Authors:  C C Broder; P L Earl
Journal:  Mol Biotechnol       Date:  1999-12-15       Impact factor: 2.695

2.  Vaccine properties of a novel marker gene-free recombinant modified vaccinia Ankara expressing immunodominant CMV antigens pp65 and IE1.

Authors:  Zhongde Wang; Corinna La Rosa; Zhongqi Li; Heang Ly; Aparna Krishnan; Joy Martinez; William J Britt; Don J Diamond
Journal:  Vaccine       Date:  2006-10-06       Impact factor: 3.641

3.  Highly efficient induction of protective immunity by a vaccinia virus vector defective in late gene expression.

Authors:  G W Holzer; G Remp; G Antoine; M Pfleiderer; O M Enzersberger; W Emsenhuber; T Hämmerle; F Gruber; C Urban; F G Falkner; F Dorner
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

4.  A pandemic influenza H1N1 live vaccine based on modified vaccinia Ankara is highly immunogenic and protects mice in active and passive immunizations.

Authors:  Annett Hessel; Michael Schwendinger; Daniela Fritz; Sogue Coulibaly; Georg W Holzer; Nicolas Sabarth; Otfried Kistner; Walter Wodal; Astrid Kerschbaum; Helga Savidis-Dacho; Brian A Crowe; Thomas R Kreil; P Noel Barrett; Falko G Falkner
Journal:  PLoS One       Date:  2010-08-16       Impact factor: 3.240

5.  Mucosal immunization of lactating female rhesus monkeys with a transmitted/founder HIV-1 envelope induces strong Env-specific IgA antibody responses in breast milk.

Authors:  Genevieve G A Fouda; Joshua D Amos; Andrew B Wilks; Justin Pollara; Caroline A Ray; Anjali Chand; Erika L Kunz; Brooke E Liebl; Kaylan Whitaker; Angela Carville; Shannon Smith; Lisa Colvin; David J Pickup; Herman F Staats; Glenn Overman; Krissey Eutsey-Lloyd; Robert Parks; Haiyan Chen; Celia Labranche; Susan Barnett; Georgia D Tomaras; Guido Ferrari; David C Montefiori; Hua-Xin Liao; Norman L Letvin; Barton F Haynes; Sallie R Permar
Journal:  J Virol       Date:  2013-04-17       Impact factor: 5.103

6.  Immunogenicity and safety of defective vaccinia virus lister: comparison with modified vaccinia virus Ankara.

Authors:  B T Ober; P Brühl; M Schmidt; V Wieser; W Gritschenberger; S Coulibaly; H Savidis-Dacho; M Gerencer; F G Falkner
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

7.  Generation of transduction-competent retroviral vectors by infection with a single hybrid vaccinia virus.

Authors:  Christian Konetschny; Georg W Holzer; Carsten Urban; Thomas Hämmerle; Josef Mayrhofer; Falko G Falkner
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

8.  Vectors based on modified vaccinia Ankara expressing influenza H5N1 hemagglutinin induce substantial cross-clade protective immunity.

Authors:  Annett Hessel; Michael Schwendinger; Georg W Holzer; Klaus K Orlinger; Sogue Coulibaly; Helga Savidis-Dacho; Marie-Luise Zips; Brian A Crowe; Thomas R Kreil; Hartmut J Ehrlich; P Noel Barrett; Falko G Falkner
Journal:  PLoS One       Date:  2011-01-24       Impact factor: 3.240

9.  A selectable and excisable marker system for the rapid creation of recombinant poxviruses.

Authors:  Julia L Rintoul; Jiahu Wang; Don B Gammon; Nicholas J van Buuren; Kenneth Garson; Karen Jardine; Michele Barry; David H Evans; John C Bell
Journal:  PLoS One       Date:  2011-09-08       Impact factor: 3.240

10.  Pre-clinical efficacy and safety of experimental vaccines based on non-replicating vaccinia vectors against yellow fever.

Authors:  Birgit Schäfer; Georg W Holzer; Alexandra Joachimsthaler; Sogue Coulibaly; Michael Schwendinger; Brian A Crowe; Thomas R Kreil; P Noel Barrett; Falko G Falkner
Journal:  PLoS One       Date:  2011-09-09       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.